Market News AIOpen the app

EIKN stock news · Eikon Therapeutics, Inc.

Stories about Eikon Therapeutics, Inc. (EIKN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for EIKN

Follow Eikon Therapeutics, Inc. (EIKN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for EIKN
Free on the App Store and Google Play, or on the web.
  1. Nov 17, 2026, 9:06 AM ET · Trial

    Eikon Therapeutics got the green light from the FDA to start testing EIK1006 on prostate cancer patients.

    Good for EIKN

    Eikon received FDA clearance to test EIK1006 in people. Dosing is expected in 2027, with early safety and benefit findings in the second half; this is positive for Eikon.

  2. Oct 23, 2026, 9:19 AM ET · Market

    Eikon Therapeutics, Inc. shares new clinical data from its research at a big medical conference.

    Neutral

    Eikon reported early results from its cancer drug studies. Tumors shrank in some patients, but varied responses and frequent severe side effects leave its outlook unchanged for now.